☆ 4.5 Article

Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern

JOURNAL OF TRAVEL MEDICINE (2022)

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Sue Ann Costa Clemens et al.

Summary: A study was conducted to evaluate the safety and immunogenicity of a third dose of heterologous or homologous vaccines in Brazilian adults who had previously received two doses of CoronaVac. The results showed that a third dose of heterologous vaccines (recombinant adenoviral vectored vaccine or mRNA vaccine) significantly increased immune responses and could improve protection against infection.

LANCET (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Laurence Chu et al.

Summary: The results of the study demonstrate that a booster dose of mRNA-1273 administered more than 6 months after the primary vaccination series is safe and leads to significantly higher levels of neutralizing antibodies, potentially increasing vaccine effectiveness against SARS-CoV-2 infection and disease.

NATURE MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

添加到收藏夹

Article Infectious Diseases

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

Gururaj Rao Deshpande et al.

Summary: This study evaluated antibody responses to SARS-CoV-2 infection in COVID-19 patients up to 8 months post-infection, finding a steep increase in antibody titers till 40 days post onset of disease, followed by a partial decline till 240 days. Severe cases were associated with stronger antibody responses, and most cases maintained antibody responses for up to 8 months post onset of disease, indicating robust protection against re-infection.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Editorial Material Public, Environmental & Occupational Health

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

Pragya D. Yadav et al.

JOURNAL OF TRAVEL MEDICINE (2021)

添加到收藏夹

Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern

相关参考文献

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2

Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin

导出引文

分享论文